Unknown

Dataset Information

0

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.

ABSTRACT: Patients with smoldering multiple myeloma (SMM) are observed until progression, but early treatment may improve outcomes. We conducted a phase II trial of elotuzumab, lenalidomide, and dexamethasone (EloLenDex) in patients with high-risk SMM and performed single-cell RNA and T cell receptor (TCR) sequencing on 149 bone marrow (BM) and peripheral blood (PB) samples from patients and healthy donors (HDs). We find that early treatment with EloLenDex is safe and effective and provide a comprehensive characterization of alterations in immune cell composition and TCR repertoire diversity in patients. We show that the similarity of a patient's immune cell composition to that of HDs may have prognostic relevance at diagnosis and after treatment and that the abundance of granzyme K (GZMK)+ CD8+ effector memory T (TEM) cells may be associated with treatment response. Last, we uncover similarities between immune alterations observed in the BM and PB, suggesting that PB-based immune profiling may have diagnostic and prognostic utility.

SUBMITTER: Sklavenitis-Pistofidis R 

PROVIDER: S-EPMC10019228 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.

Sklavenitis-Pistofidis Romanos R   Aranha Michelle P MP   Redd Robert A RA   Baginska Joanna J   Haradhvala Nicholas J NJ   Hallisey Margaret M   Dutta Ankit K AK   Savell Alexandra A   Varmeh Shohreh S   Heilpern-Mallory Daniel D   Ujwary Sylvia S   Zavidij Oksana O   Aguet Francois F   Su Nang K NK   Lightbody Elizabeth D ED   Bustoros Mark M   Tahri Sabrin S   Mouhieddine Tarek H TH   Wu Ting T   Flechon Lea L   Anand Shankara S   Rosenblatt Jacalyn M JM   Zonder Jeffrey J   Vredenburgh James J JJ   Boruchov Adam A   Bhutani Manisha M   Usmani Saad Z SZ   Matous Jeffrey J   Yee Andrew J AJ   Jakubowiak Andrzej A   Laubach Jacob J   Manier Salomon S   Nadeem Omar O   Richardson Paul P   Badros Ashraf Z AZ   Mateos Maria-Victoria MV   Trippa Lorenzo L   Getz Gad G   Ghobrial Irene M IM  

Cancer cell 20221101 11

Patients with smoldering multiple myeloma (SMM) are observed until progression, but early treatment may improve outcomes. We conducted a phase II trial of elotuzumab, lenalidomide, and dexamethasone (EloLenDex) in patients with high-risk SMM and performed single-cell RNA and T cell receptor (TCR) sequencing on 149 bone marrow (BM) and peripheral blood (PB) samples from patients and healthy donors (HDs). We find that early treatment with EloLenDex is safe and effective and provide a comprehensive  ...[more]

Similar Datasets

Genomics Single-cell RNA-sequencing identifies immune biomarkers of response to immunotherapy in patients with high-risk Smoldering Myeloma
| PRJNA740370 | ENA
Genomics Single-cell RNA-sequencing identifies immune biomarkers of response to immunotherapy in patients with high-risk Smoldering Myeloma
| PRJNA740371 | ENA
Unknown Genomic analysis of high-risk smoldering multiple myeloma.
| S-EPMC3436247 | biostudies-literature
Unknown Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma.
| S-EPMC5728141 | biostudies-literature
Unknown Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma.
| S-EPMC10951870 | biostudies-literature
Unknown Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression.
| S-EPMC7898535 | biostudies-literature
Unknown Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database.
| S-EPMC11621302 | biostudies-literature
Unknown Adoptive Immunotherapy and High-Risk Myeloma.
| S-EPMC10177276 | biostudies-literature
Unknown Risk Stratification and Treatment in Smoldering Multiple Myeloma.
| S-EPMC8750018 | biostudies-literature
Unknown High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
| S-EPMC7069728 | biostudies-literature